Association Between Serum Amylin, Irisin, and Sirtuin 1 in Male Patients with Type 2 Diabetes and Diabetic Nephropathy.
Type 2 diabetes mellitus (DM) is a progressive disease worldwide that leads to various complications. Given the roles of the hormones amylin and irisin and the enzyme sirtuin 1 (SIRT1) in metabolism and oxidative stress, we focused on these parameters in the serum of patients.
We investigated the associations between serum amylin, irisin, and SIRT1 levels and diabetic nephropathy (DN), an important complication of DM.
Patients with DM (n = 50) and DN (n = 50) were included in this single-center cross-sectional study. Various parameters were measured from fasting blood and urine samples. Serum amylin, irisin, and SIRT1 levels were measured using enzyme-linked immunosorbent assay kits. In addition to demographic characteristics, fasting blood sugar, glycated hemoglobin, serum insulin, urine creatinine, and estimated glomerular filtration rate were used to classify participants.
After adjustment for age, diabetes duration, body mass index, fasting blood sugar, glycated hemoglobin, homeostasis model assessment of insulin resistance, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, amylin levels were significantly lower, whereas irisin and SIRT1 levels were significantly higher, in the DN group than in the DM group. Multivariable logistic regression showed that higher amylin levels were associated with lower odds of DN, whereas higher irisin and SIRT1 levels were associated with higher odds of DN. Receiver operating characteristic curves were used to evaluate the ability of these biomarkers to discriminate between the DM and DN groups. In addition, mediation analysis showed associations among irisin, SIRT1, and DN.
These findings suggest that irisin and SIRT1 are associated with DN status in patients with diabetes and may provide insights into metabolic complications. However, longitudinal studies are needed to establish causality.
We investigated the associations between serum amylin, irisin, and SIRT1 levels and diabetic nephropathy (DN), an important complication of DM.
Patients with DM (n = 50) and DN (n = 50) were included in this single-center cross-sectional study. Various parameters were measured from fasting blood and urine samples. Serum amylin, irisin, and SIRT1 levels were measured using enzyme-linked immunosorbent assay kits. In addition to demographic characteristics, fasting blood sugar, glycated hemoglobin, serum insulin, urine creatinine, and estimated glomerular filtration rate were used to classify participants.
After adjustment for age, diabetes duration, body mass index, fasting blood sugar, glycated hemoglobin, homeostasis model assessment of insulin resistance, triglycerides, low-density lipoprotein cholesterol, and high-density lipoprotein cholesterol, amylin levels were significantly lower, whereas irisin and SIRT1 levels were significantly higher, in the DN group than in the DM group. Multivariable logistic regression showed that higher amylin levels were associated with lower odds of DN, whereas higher irisin and SIRT1 levels were associated with higher odds of DN. Receiver operating characteristic curves were used to evaluate the ability of these biomarkers to discriminate between the DM and DN groups. In addition, mediation analysis showed associations among irisin, SIRT1, and DN.
These findings suggest that irisin and SIRT1 are associated with DN status in patients with diabetes and may provide insights into metabolic complications. However, longitudinal studies are needed to establish causality.
Authors
Sabih Wajdi Sabih Wajdi, Mohyadini Mohyadini, Abdlwhab Abdlwhab, E Jassim E Jassim, Bathaie Bathaie
View on Pubmed